Introduction
The landscape of COVID-19 testing has been dynamic, with the FDA playing a crucial role in ensuring the availability of reliable tests. Initially, COVID-19 tests were authorized for use under Emergency Use Authorizations (EUAs). This approach allowed for the rapid deployment of tests during the early phases of the pandemic
Listen to the Episode Here:
The Role of Emergency Use Authorizations (EUAs)
The FDA issued EUAs for numerous COVID-19 tests following the Secretary’s declaration related to in vitro diagnostic tests on February 4, 2020. Tests with active EUAs remain usable as long as they are available and not expired. The EUA process differs from the traditional review pathways, with the FDA determining that a product may be effective for the intended use during the emergency, and that the known and potential benefits outweigh the risks.
Transitioning to Traditional Marketing Authorization
As the pandemic evolves, the FDA is working with test developers to pursue marketing authorization through traditional premarket review pathways. This process will allow these tests to continue to be used beyond the time allowed by emergency use authorization. The traditional review process requires the FDA to consider whether there is reasonable assurance of safety and effectiveness when the device is used as intended. The FDA has also issued guidance to help EUA holders transition to traditional marketing authorization
What This Means for COVID-19 Testing
The transition from EUAs to traditional marketing authorization signifies a shift towards a more established regulatory process for COVID-19 tests. While tests authorized under EUAs are still valid as long as they are available and not expired, the push for traditional marketing authorization will ensure long term availability of these tests
